Author/Authors :
Agarwal, Amit Department of Medicine - University of Arizona - Tucson - AZ, USA , Husnain, Muhammad Department of Medicine - University of Arizona - Tucson - AZ, USA , Riaz, Irbaz Bin Department of Medicine - University of Arizona - Tucson - AZ, USA , Kurtin, Sandra Banner University Medical Center Tucson - Department of Hematology Oncology - University of Arizona - Tucson - AZ, USA , Barkett, Nikki Banner University Medical Center Tucson - Department of Hematology Oncology - University of Arizona - Tucson - AZ, USA
Abstract :
Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed andrefractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed themedian overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells whichwas studied in phase I/II trials for treatment of these patients with relapsed refractory multiple myeloma. It showed an overallresponserateof36%andamedianoverallsurvival(OS)of17monthsinthesepatients.Wereportacaseof40-year-oldmanwithimmunoglobulin D (IgD) multiple myeloma whose disease was refractory to at least 5 different chemotherapy regimens includingproteasome inhibitors and immunomodulatory drugs. The clinical studies assessing daratumumab did not include any patientswith IgD myeloma which is a rare form of multiple myeloma and to our knowledge is the first study reporting use of daratumumabin IgD myeloma.
